再鼎医药(09688.HK) 公布截至去年12月底止全年业绩,按美国公认会计准则编制,营业额3.98亿美元(下同),按年升49.1%。亏损收窄至2.57亿元,上年同期蚀3.35亿元;每股亏损0.26元。不派息。(js/w)过往派息公布日期派息事项派息内容2025/02/27末期业绩无派息2024/11/12第三季业绩无派息2024/08/07中期业绩无派息2024/05/09第一季业绩无派息(港股...
Source Link再鼎医药(09688.HK) 公布截至去年12月底止全年业绩,按美国公认会计准则编制,营业额3.98亿美元(下同),按年升49.1%。亏损收窄至2.57亿元,上年同期蚀3.35亿元;每股亏损0.26元。不派息。(js/w)过往派息公布日期派息事项派息内容2025/02/27末期业绩无派息2024/11/12第三季业绩无派息2024/08/07中期业绩无派息2024/05/09第一季业绩无派息(港股...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.